《新股消息》高視醫療(02407.HK)今起招股 一手入場費5,191.81元
內地眼科醫療器械商高視醫療(02407.HK)公布招股詳情,擬全球發售1,306.86萬股,香港公開發售約佔一成,國際發售約佔九成。每股招股價為51.4元。每手100股計,一手入場費5,191.81元。該股今日(11月30日)起招股,下周一(12月5日)中午截止,預期將於12月12日掛牌。聯席保薦人為大摩及海通國際。
公司上市引入兩名基石投資者,包括「無錫視高、無錫高視及中德基金」,以及CLKiwi,合共認購4,140萬美元股份。
此外,公司上市料淨集資約2.83億元,當中約25%將用於升級人工晶體產品以及生產人工晶體所用的疏水性及親水性材料的研發能力;約7%將用於眼科診斷產品的研發;約6.2%將用於視光產品的研發;約29%將於上市後兩年內用於提高產能及增強製造能力;約9.5%將於上市後兩年內用於透過聘請專門從事眼科醫療器械銷售及營銷的人員;約10.6%將用作營運資金及一般企業用途;約12.7%用於償還公司就收購泰靚所產生利率為5%的夾層融資貸款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.